Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Domain Therapeutics Enters into Collaboration with XOMA

Published: Wednesday, February 05, 2014
Last Updated: Wednesday, February 05, 2014
Bookmark and Share
DTect-All™ platform will be used to screen for GPCR-directed allosteric modulator antibodies.

Domain Therapeutics has announced that it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

XOMA, a California based U.S. public company, focuses its research on allosteric modulation which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.

Domain Therapeutics has extensive expertise in allosteric modulation and operates DTect-All™, a platform that has successfully discovered small molecule allosteric modulators for a wide range of GPCRs.

Domain Therapeutics and XOMA will jointly evaluate the robustness of DTect-All to identify allosteric modulator antibodies of a first target. If successful, the partners may elect to further collaborate on other GPCRs from a set of preselected targets for which, under the terms of the agreement, Domain Therapeutics will be eligible for an upfront payment and certain undisclosed milestones per target, as well as undisclosed royalties. Domain will have the right to offer its DTect-All platform to discover antibody-based drugs to other companies outside the scope of the set of GPCRs selected by XOMA.

“We strongly believe that XOMA is the partner of choice to discover allosteric modulator antibodies targeting GPCRs and that applying DTect-All to this area of research will represent a real breakthrough,” said Pascal Neuville, board director and CEO of Domain Therapeutics. “We anticipate that this collaboration will enhance our drug discovery capabilities by opening the door to other biologics. It will further strengthen Domain Therapeutics’ position as a key player in GPCR drug discovery.”

The therapeutic antibodies market is expected to grow from USD 45 billion in 2011 to USD 58 billion in 2016 (BCC Research, 2012). GPCRs, as a major class of therapeutic targets, are expected to be a large part of it if technology obstacles can be overcome.

The current paradigm of GPCR-targeting antibody discovery relies on screening techniques lacking robustness and reproducibility making the process very challenging and resulting in the failure of many discovery programs.

So far, just one GPCR antibody product has reached the market, however, a pipeline of Phase II candidates does confirm strong interest by the pharmaceutical industry.

Allosteric modulator antibodies are expected to display superior selectivity and safety over classic GPCR drugs. Domain’s technology has the potential to overcome the limitations of other technologies to discover this class of antibodies with novel mode of action.

The majority of ongoing GPCR antibody discovery and development programs are dedicated to the identification of antagonist entities, which induce an inhibition of the GPCR signaling.

By facilitating access to this new category of drugs, DTect-All will generate differentiated and valuable assets for companies like XOMA, who are developing GPCR-targeting antibodies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domain Therapeutics Appoints Professor Michel Bouvier
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs.
Tuesday, September 23, 2014
Domain Therapeutics Opens a North American Subsidiary at Montreal's NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All™ technology.
Tuesday, January 21, 2014
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University Sign Agreement
New licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.
Thursday, December 26, 2013
Domain Therapeutics and Ono Sign Collaboration Agreement
Collaboration agreement in the field of GPCR-based drug discovery.
Tuesday, October 23, 2012
Domain Therapeutics Closes EUR Two Million Funding Round
The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs.
Wednesday, July 18, 2012
Domain Therapeutics Wins EUR 933,000 Grant for Schizophrenia Project
GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies.
Wednesday, March 14, 2012
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease.
Monday, January 17, 2011
Scientific News
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos